predisposit
cancer
patient
infecti
diseas
contribut
graviti
prognosi
well
document
current
success
therapi
malign
infect
unpreced
howev
overal
comorbid
condit
still
major
problem
manag
patient
paradox
degre
problem
contain
infecti
complic
directli
associ
vigor
anticanc
therapeut
regimen
object
chapter
provid
date
overview
understand
infecti
complic
cancer
patient
base
type
infect
immun
respons
object
chapter
provid
overview
current
statu
subject
outlin
major
aspect
infecti
diseas
one
major
caus
morbid
mortal
cancer
patient
emphasi
latest
public
fi
eld
spectrum
infecti
agent
clinic
manifest
diseas
well
rang
diagnost
marker
technolog
detect
evolv
featur
never
end
battl
genet
nonself
malign
infecti
invad
confl
ict
due
develop
new
infectionand
cancer
defens
mechan
one
hand
rapid
progress
therapeut
intervent
oncogenesi
develop
infecti
diseas
ultim
root
compromis
abil
immun
system
defend
nonself
either
malign
infecti
compon
underli
mechan
two
group
disord
complex
often
interconnect
instanc
pattern
turn
viciou
circl
demonstr
cancer
viral
etiolog
patient
hpv
relat
squamou
cell
carcinoma
hiv
associ
kaposi
sarcoma
hcv
induc
hepatocellular
carcinoma
eventu
becom
prone
viral
fungal
bacteri
infect
genesi
infecti
complic
cancer
patient
base
local
tumorinduc
effect
mechan
gener
immunosuppress
induc
cancerrel
process
iatrogen
outcom
therapeut
regimen
sutton
specifi
c
characterist
cours
outcom
infecti
diseas
cancer
patient
defi
ned
numer
factor
discuss
chapter
base
type
infect
immun
system
compon
involv
bacteria
repres
common
pathogen
cancer
associ
infect
bacteri
sepsi
continu
lead
caus
morbid
toxic
death
children
receiv
intens
therapi
cancer
alexand
et
al
well
acknowledg
oncolog
patient
suscept
bacteri
infect
system
spread
due
tumorrel
iatrogen
immunosuppress
compris
classic
clinic
combin
sever
neutropenia
fever
hypotens
headach
rasool
hassan
et
al
acut
bacteri
infect
neg
impact
surviv
increas
mortal
adult
pediatr
patient
solid
cancer
hematolog
malign
lanoix
et
al
atti
et
al
de
oliveira
et
al
elucid
specifi
c
mechan
marker
oncogenesi
cancer
associ
infect
allow
develop
target
specifi
c
therapi
exampl
recogn
helicobact
pylori
one
major
caus
gastric
cancer
recent
identifi
ed
gastric
stemprogenitor
cell
marker
villinpromot
mist
gastric
cancer
stem
cell
marker
reveal
novel
inform
tumor
cell
behavior
diseas
progress
implic
therapeut
ding
zheng
new
insight
current
emerg
concern
complex
infectioncancerinfect
mechan
interplay
two
major
concept
oncogen
role
infl
ammatori
cytokin
ii
chemokin
axisbas
induct
metastasi
nich
recent
report
system
infl
ammat
trigger
gastrointestin
tract
bacteria
play
pivot
role
oncogenesi
prostat
gland
poutahidi
et
al
recent
research
confi
rming
concept
infl
ammat
critic
compon
tumor
progress
came
studi
address
correl
oral
bacteria
l
infect
cancer
infl
ammat
caus
periodont
infect
link
cancer
lung
kidney
pancrea
hematolog
oral
cancer
pendyala
et
al
concept
metastat
spread
cancer
promot
bacteri
infect
propos
base
studi
axi
demonstr
acut
bacteri
infect
commonli
seen
patient
cancer
link
increas
metastasi
lung
smith
kang
model
bacteriainduc
acut
lung
infl
ammat
use
studi
effect
lung
metastasi
mice
acut
lung
infect
dramat
increas
cancer
cell
home
lung
lung
metastasi
also
confi
rmed
axi
play
import
role
chang
describ
prepar
favor
metastat
nich
yan
et
al
allogen
stem
cell
transplant
part
therapeut
modul
numer
cancer
previou
studi
demonstr
approxim
allogen
hematopoiet
stem
cell
transplant
recipi
develop
clostridium
diffi
cile
infect
transplant
greatli
exceed
rate
patient
popul
alonso
kamboj
kinnebrew
et
al
fungi
second
common
pathogen
bacteria
caus
cancerassoci
infect
adult
pediatr
patient
solid
organand
hematolog
malign
organ
commonli
lung
kim
et
al
less
frequent
associ
high
mortal
rate
pediatr
cancer
patient
central
nervou
system
carter
et
al
affect
almost
adult
patient
acut
myeloid
leukemia
subject
chemotherapi
develop
invas
fungal
infect
neofyto
et
al
pediatr
oncolog
invas
fungal
infect
also
frequent
potenti
fatal
complic
mor
et
al
although
solid
tumor
compris
vast
major
cancer
morbid
mortal
due
fungal
infect
higher
patient
hematolog
malign
invas
aspergillu
infect
one
common
fungal
infect
observ
patient
hematolog
malign
subject
allogen
hematopoiet
stem
cell
transplant
de
nauroi
et
al
pediatr
oncolog
patient
develop
fungal
infect
myeloid
leukemia
acut
lymphoblast
leukemia
primari
diagnosi
mor
et
al
prolong
neutropenia
either
primari
secondari
genesi
due
intens
chemotherapi
regimen
major
predispos
factor
invas
fungal
infect
de
nauroi
et
al
mousset
et
al
addit
fungal
infect
develop
complic
protract
use
venou
cathet
lai
et
al
aspergillosi
report
highest
incid
candidiasi
second
neofyto
et
al
mor
et
al
de
nauroi
et
al
fungal
type
infect
occur
less
frequent
complic
adult
pediatr
cancer
patient
kim
et
al
caselli
et
al
increas
intens
chemotherapeut
regimen
rise
resist
fungal
infect
antifung
drug
prompt
search
new
optim
prophylact
therapeut
approach
antifung
drug
often
given
prophylact
patient
persist
fever
shown
decreas
mortal
rate
johansen
gotzsch
trimethoprimsulfamethoxazol
prophylact
administ
chemotherapi
regimen
shown
effect
prevent
pneumocysti
pneumonia
children
solid
tumor
leukemia
lymphoma
caselli
et
al
howev
caution
choic
primari
secondari
antifung
prophylaxi
recommend
use
secondari
prophylaxi
may
reduc
system
fungal
infect
frequenc
time
increas
risk
colon
infect
azoleresist
fungal
strain
gedik
et
al
sinc
demonstr
prolong
durat
neutropenia
one
risk
factor
onset
invas
aspergillosi
addit
granulocytecolonystimul
factor
therapeut
prophylact
protocol
recommend
van
de
peppel
et
al
viral
infect
increasingli
recogn
seriou
caus
morbid
mortal
cancer
patient
new
technolog
emerg
detect
respect
addit
challeng
accur
time
diagnosi
administr
appropri
antivir
therapi
group
patient
babadi
et
al
special
import
still
open
question
interplay
antivir
antitumor
immun
mechan
effect
time
vaccin
relev
chemotherapi
regimen
pediatr
adult
oncolog
practic
despit
signifi
cant
advanc
manag
pediatr
cancer
infl
uenza
epidemiolog
outcom
infl
uenza
pediatr
oncolog
patient
alter
past
sever
decad
carr
et
al
although
infl
uenza
usual
present
mild
ill
children
hematolog
condit
solid
tumor
increas
risk
complic
may
lead
delay
anticanc
therapi
increas
hospit
antibiot
usag
ozdemir
et
al
though
infl
uenza
common
viral
infect
one
long
list
virus
rhinoviru
parainfl
uenza
viru
adenoviru
respiratori
syncyti
viru
human
parechoviru
bocaviru
metapneumoviru
human
coronaviru
occur
neutropen
pediatr
patient
codetect
virus
uncommon
occur
infect
variou
combin
benit
et
al
cancer
patient
uniqu
problem
associ
hepat
b
hbv
hepat
c
hcv
viru
infect
special
concern
risk
reactiv
infect
due
viral
replic
result
immunosuppress
effect
chemotherapi
gener
new
emerg
modal
target
therapi
date
differ
outcom
respect
therapi
use
alemtuzumab
brentuximab
imatinib
cetuximab
panitumumab
ppilimumab
report
random
trial
need
establish
algorithm
issu
yazici
et
al
also
consider
problem
balanc
chemotherapi
antivir
medic
regimen
time
administr
patient
chemotherapi
postpon
complet
antivir
cours
therapi
other
subject
viral
infect
therapi
treatment
cancer
borchardt
torr
one
larg
studi
japan
evalu
patient
breast
cancer
report
chemotherapi
breast
cancer
patient
hcv
infect
feasibl
accord
experi
viral
load
nt
chang
chemotherapi
miura
et
al
elucid
need
clarifi
whether
outcom
cancer
type
factorspecifi
c
cancer
patient
substanti
increas
risk
herp
zoster
relat
complic
risk
herp
zoster
infect
cancer
patient
compar
gener
popul
higher
doubl
incid
patient
hematolog
malign
solid
tumor
includ
brain
lung
breast
esophag
gastric
colorect
cancer
hata
et
al
habel
et
al
also
suggest
herp
zoster
use
marker
risk
malign
sinc
higher
incid
malign
follow
episod
herp
zoster
men
women
age
group
year
iglar
et
al
mechan
hiv
oncogenesi
interconnect
adult
pediatr
patient
comorbid
complex
multifactori
hivassoci
immun
activ
infl
ammat
one
hand
acceler
immun
senesc
favor
cancer
develop
hivinfect
patient
enhanc
risk
sever
cancer
includ
lung
anal
cancer
hepatocellular
carcinoma
hodgkin
lymphoma
kaposi
sarcoma
sever
cancer
compar
gener
popul
sigel
et
al
manag
cancer
hiv
patient
current
intens
research
specifi
c
malign
highli
activ
antiretrovir
therapi
haart
chang
cours
hiv
infect
haart
reduc
aidsdefi
nedmalign
increas
incid
sever
nonaidsdefi
nedmalign
chiappini
et
al
adenocarcinoma
lung
preval
nonaidsdefi
ning
cancer
haart
era
four
time
greater
incid
hivinfect
individu
gener
popul
two
major
problem
current
associ
manag
lung
cancer
hiv
patent
diagnosi
often
late
onset
younger
popul
clinic
mask
pulmonari
infect
common
among
hivinfect
individu
addit
although
increas
experi
use
radiat
chemotherapi
hivinfect
patient
surgic
option
need
prospect
studi
popul
frequent
exclud
particip
cancer
trial
mani
et
al
present
necess
includ
cancer
screen
hivinfect
patient
sigel
et
al
infect
increas
morbid
mortal
cancer
patient
regimen
antiinfect
therapi
interfer
chemotherapi
treatment
modal
group
patient
mani
case
lead
necess
postpon
antitumor
therapi
manag
infect
vice
versa
delay
antiinfect
medic
chemotherapi
complet
light
neg
impact
togeth
rise
antibiot
resist
develop
prevent
approach
preclud
almost
inevit
infecti
complic
especi
neutropen
patient
highli
desir
need
infect
prophylaxi
also
grow
hematopoiet
cell
transplant
recipi
due
overal
improv
treatment
last
two
decad
surviv
durat
increas
incid
posttransplant
infect
particularli
caus
respiratori
virus
concomitantli
increas
lifespan
lack
direct
antivir
therapi
virus
promot
use
inactiv
infl
uenza
vaccin
hematopoiet
cell
transplant
recipi
shah
et
al
report
benefi
ts
limit
vaccin
cancer
patient
numer
contradictori
overal
trend
infl
uenza
vaccin
benefi
cial
immunocompromis
patient
signifi
cantli
lower
odd
infl
uenzalik
ill
patient
hiv
infect
patient
cancer
transplant
recipi
beck
et
al
multicent
observ
studi
found
cancer
hematopoiet
stem
cell
transplant
recipi
infl
uenza
incid
pneumonia
mortal
howev
death
observ
among
vaccin
patient
dignani
et
al
studi
kim
et
al
address
immunogen
infl
uenza
vaccin
colorect
cancer
patient
base
antibodi
titer
blood
sampl
data
show
accept
immun
respons
infl
uenza
vaccin
without
signifi
cant
advers
effect
support
recommend
annual
infl
uenza
vaccin
colorect
cancer
patient
kim
et
al
simpl
prognost
measur
propos
evalu
vaccin
respons
viru
studi
demonstr
absolut
lymphocyt
count
lower
normal
limit
age
prior
vaccin
predict
posit
respons
infl
uenza
vaccin
pediatr
cancer
patient
treat
chemotherapi
mavinkurvegroothui
et
al
howev
caution
suggest
respect
effect
vaccin
cancer
patient
undergo
chemotherapi
conclus
studi
shehata
colleagu
although
activ
immun
cancer
patient
shown
confer
protect
immun
sever
infect
similar
rate
healthi
individu
immun
respons
infl
uenza
vaccin
patient
receiv
chemotherapi
consist
weaker
shehata
karim
clarifi
cation
optim
time
vaccin
cancer
patient
need
addit
one
recent
studi
neg
fi
nding
effect
infl
uenza
vaccin
ovarian
cancer
patient
report
data
studi
shown
patient
ovarian
cancer
almost
uniformli
unabl
mount
meaning
antibodi
respons
infl
uenza
vaccin
despit
cdc
recommend
patient
undergo
chemotherapi
receiv
infl
uenza
vaccin
littl
evid
support
serolog
effect
patient
chu
et
al
compon
innat
adapt
immun
involv
shape
cours
malign
associ
infecti
diseas
ultim
prognosi
patient
addit
cellular
immun
dysfunct
chang
includ
alter
cytokin
profi
le
humor
immun
reaction
special
focu
chapter
latest
updat
rapidli
evolv
fi
eld
studi
dendrit
regulatori
cell
neutropeniarel
complic
elucid
mechan
immun
system
dysfunct
type
cancer
natur
infect
recent
even
individu
patient
level
allow
develop
target
specifi
c
therapi
dendrit
cell
dc
cell
among
major
player
sustain
physiolog
immun
condit
compris
two
function
distinct
popul
cell
promot
immun
sustain
immun
toler
within
cell
function
subtyp
easili
identifi
ed
effector
regulatori
treg
cell
respect
classifi
cation
differ
subgroup
among
dendrit
cell
much
complic
origin
dc
discov
cell
myeloid
origin
mainli
antigenpres
function
thu
cell
promot
mechan
adapt
immun
steinman
later
recogn
depend
dc
matur
statu
steinman
et
al
hematopoiet
lineag
origin
et
al
express
costimulatori
mhc
molecul
play
either
immunostimulatori
tolerogen
immunosuppress
role
hurwitz
watkin
zhong
et
al
addit
chang
immunostimulatori
tolerogen
statu
induc
dc
via
differ
mechan
number
malign
also
taken
consider
malign
aris
older
popul
henc
agerel
declin
hematopoiet
cell
abil
selfrenew
also
contribut
immunocompromis
condit
cancer
patient
year
old
lipschitz
balducci
et
al
shurin
et
al
abil
malign
cell
switch
dc
function
immunostimulatori
immunosuppress
cell
one
essenti
immunomodulatori
featur
onset
malign
complic
network
express
ligandreceptor
axi
chang
signal
transduct
lead
alter
function
profi
le
dc
subpopul
twofold
outcom
one
hand
part
tumor
defens
mechan
protect
malign
mass
immun
reaction
allow
unhind
growth
hand
tolerogen
function
dc
lead
gener
immunosuppress
contribut
onset
infecti
diseas
last
decad
new
insight
particular
mechan
contribut
tumorinduc
chang
dc
function
result
increas
suscept
infecti
diseas
report
includ
local
system
mechan
employ
tumor
affect
dc
function
collect
result
inhibit
dc
differenti
hematopoiet
progenitor
shurin
et
al
tourkova
et
al
hargadon
chang
phenotyp
function
zhong
et
al
aalamianmathei
et
al
karthau
et
al
chao
et
al
dendrit
cell
often
accumul
around
tumor
howev
mere
presenc
refl
ect
input
overal
immun
henc
nt
prognost
valu
could
either
part
robust
antitumor
immun
esch
et
al
iida
et
al
may
play
essenti
role
tumor
immun
escap
zhong
et
al
wu
et
al
dudek
et
al
dc
phenotyp
valuabl
tool
defi
ning
matur
function
statu
multipl
group
report
data
contribut
optim
phenotyp
panel
marker
tolerogenicregulatori
dc
cancer
shown
prostat
cancer
express
costimulatori
molecul
decreas
aalamianmathei
et
al
also
report
evalu
tumorinfi
ltrate
dc
perform
util
larger
panel
includ
also
dcsign
dclamp
marker
karthau
et
al
detect
dcsign
import
intercellular
adhes
molecul
interact
carbohydr
structur
cancer
cell
interact
lead
immunosuppress
respons
dc
via
inhibit
matur
chao
et
al
also
suggest
differ
level
express
mhc
costimulatori
molecul
repres
pattern
differ
subset
regulatori
dc
zhong
et
al
major
cancer
relat
factor
trigger
immunosuppress
dc
function
interleukin
shurin
et
al
lindenberg
et
al
kaebisch
et
al
liu
et
al
caux
et
al
wu
et
al
recent
insight
mechan
dcrelat
immunocompromis
condit
cancer
cancerassoci
infect
led
develop
numer
therapeut
approach
util
dcbase
vaccin
mayordomo
et
al
b
tute
et
al
mayordomo
et
al
burgdorf
cui
et
al
duncan
et
al
fadul
et
al
niu
et
al
ridolfi
et
al
rosenblatt
et
al
van
tendeloo
et
al
suso
et
al
immunotherapi
fang
et
al
gao
et
al
ghansah
et
al
kobayashi
et
al
lu
et
al
wimmer
et
al
yuan
et
al
zhao
et
al
regulatori
treg
cell
play
essenti
role
neg
regul
immun
respons
physiolog
diseas
condit
evid
mount
support
contribut
process
oncogenesi
grow
number
cancer
shown
possess
abil
util
differ
mechan
attract
treg
cell
util
defens
immun
reaction
affect
individu
role
treg
cell
enhanc
morbid
cancer
associ
infect
via
local
gener
immunosuppress
mechan
traffi
cking
pattern
treg
cell
alter
tumorsecret
cytokin
chemokin
molecul
induc
recruit
vicin
tumor
provid
malign
mass
shield
suppress
antitumor
immun
respons
allow
uninhibit
tumor
growth
also
result
compromis
antiinfect
immun
among
list
cohort
tumor
ovarian
carcinoma
curiel
et
al
breast
tumor
gobert
et
al
mesothelioma
hegman
et
al
hodgkin
lymphoma
ishida
et
al
myelodysplast
syndrom
kotsianidi
et
al
gastric
cancer
mizukami
et
al
ohtani
et
al
malign
plural
mesothelioma
effus
qin
et
al
shimizu
et
al
lung
adenocarcinoma
wald
et
al
among
chemokin
molecul
alter
express
report
contribut
distort
traffi
cking
pattern
treg
cell
cancer
fi
nding
trigger
new
direct
search
immunomodulatori
therapi
target
chemokin
molecul
express
attempt
rectifi
treg
cell
traffi
cking
function
result
imped
tumor
growth
amelior
gener
immunosuppress
infect
complic
effect
treg
cell
deplet
regress
oral
fi
brosarcoma
increas
surviv
demonstr
util
mous
model
ab
administr
result
deplet
treg
complet
regress
tumor
whelan
et
al
follow
studi
propos
modifi
cation
use
ab
shown
target
low
subset
assur
discern
deplet
treg
cell
among
cell
popul
weiss
et
al
cell
surfac
enzym
suppress
immun
adopt
experi
tregdefi
cient
mice
demonstr
protumorogen
effect
treg
cell
depend
express
vivo
blockad
select
inhibitor
mab
reduc
tumor
growth
metastasi
stagg
et
al
prostaglandin
play
role
induct
treg
cell
interrupt
signal
pathway
suggest
altern
approach
reduct
tumor
protect
function
treg
cell
baratelli
et
al
interest
adapt
mesenchym
stem
cell
msc
transplant
cancer
therapi
lead
fi
nding
migrat
msc
site
tumor
growth
produc
inhibit
signal
associ
normal
treg
number
dramat
reduc
pulmonari
hepat
metastas
ling
et
al
xlink
nuclear
transcript
factor
consid
defi
ning
marker
treg
popul
sakaguchi
hori
et
al
recent
shown
play
domin
role
develop
function
treg
cell
also
tumor
suppressor
factor
heinz
et
al
fi
nding
special
interest
sinc
demonstr
tumor
cytotox
mediat
via
differ
signal
pathway
compar
enhanc
treg
cell
function
discrimin
allow
develop
targetspecifi
c
therapi
aim
augment
treg
cell
antitumor
effect
alter
immunosuppress
function
heinz
et
al
neutropenia
neutrophil
among
cell
act
fi
rst
line
defens
infect
mediat
innat
immun
neutropenia
defi
ned
absolut
neutrophil
count
newburg
dale
common
complic
cancer
neutropenia
develop
result
malign
affect
hematopoiesi
directli
via
skew
product
growth
factor
cytokin
addit
neutropenia
grow
concern
result
widespread
use
aggress
chemotherapi
nesher
rolston
sever
aspect
neutropenia
current
thorough
investig
patient
cancer
associ
infect
shown
group
patient
neutropenia
associ
increas
infect
relat
morbid
mortal
directli
correl
occurr
sepsi
cho
et
al
cancer
patient
febril
neutropenia
episod
higher
incid
secondari
infect
presenc
central
intraven
cathet
diarrhea
invas
aspergillosi
among
predispos
risk
factor
azap
et
al
cancer
patient
febril
neutropenia
develop
associ
hematolog
neoplasm
undergo
highdos
chemotherapi
regimen
develop
bloodstream
infect
gramneg
multidrugresist
bacteria
report
prolong
hospit
stay
rosa
goldani
addit
determin
mechan
underli
onset
neutropenia
interest
respect
discern
infecti
versu
steril
infl
ammat
frequent
challeng
cancer
patient
model
identifi
infect
noninfect
patient
base
level
list
variabl
includ
acut
phase
protein
cytokin
measur
coagul
metabol
organ
stress
iron
turnov
propos
diagnost
evalu
febril
neutropen
hematolog
patient
wennera
et
al
evalu
risk
onset
neutropenia
also
play
central
role
develop
optim
prophylact
chemotherapeut
regimen
durat
weycker
et
al
suscept
cancer
patient
variou
infect
bacteri
fungal
viral
common
due
cancerinduc
factor
iatrogen
outcom
aggress
therapeut
regimen
mechan
evok
immunocompromis
condit
cancer
origin
contribut
higher
incid
aggress
cours
infecti
complic
group
patient
complex
interconnect
highest
risk
onset
infecti
complic
associ
morbid
mortal
seen
patient
receiv
chemotherapi
treatment
hematolog
malign
common
occurr
patient
develop
neutropenia
due
chemic
induc
suppress
hemopoiesi
alreadi
compromis
malign
iron
case
incid
infect
concomitantli
increas
lifespan
prolong
due
success
anticanc
therapi
thu
ultim
goal
discern
dichotomi
chemotherapymedi
anticanc
immunosuppress
effect
direct
impact
manag
infect
patient
especi
import
light
increas
antibiot
resist
new
insight
dc
treg
cellmedi
reaction
lead
morbid
cancer
patient
infecti
complic
permit
develop
novel
targetspecifi
c
immunomodulatori
therapeut
approach
